C Boyd Clarke

Bio

Boyd Clarke joined ProQuest in 2007 as a Venture Advisor. Mr. Clarke brings extensive senior executive experience to ProQuest having spent over ten years at the helm of several biotechnology companies. He is currently Chairman of the Board of QLT Inc. and Mersana Therapeutics, a ProQuest portfolio company. In addition, Mr. Clarke serves on the Board of Rib-X Therapeutics. He was formerly CEO of Neose Technologies. Mr. Clarke was also the CEO of Aviron, which was acquired by MedImmune. Prior to Aviron, Mr. Clarke was President and CEO of US Bioscience, a former ProQuest portfolio company, which was also acquired by MedImmune. Before US Bioscience, Mr. Clarke held a number of positions in sales and marketing and in general management at Merck & Co. including being the first President of Paster-Merieux MSD, and Vice President of Merck Vaccines. BS in Biochemistry and an MA in History from the University of Calgary.